ESMO CONGRESS 2019

BARCELONA 27 settembre 01 ottobre 2019

Scarica il file 

Scarica il file 

Scarica il file 

ABSTRACT XX

Congresso Nazionale AIOM 2018

ROMA 16 - 17 - 18 novembre 2018

Scarica il file 

Scarica il file 

Scarica il file  

· DURATION OF OXALIPLATIN - CONTAINING ADJUVANT.

  THERAPY FOR STAGE III COLON CANCER: ASCO CLINICAL PRACTICE GUIDELINE

Scarica il file  

· IMPACT OF METFORMIN USE AND DIABETIC STATUS DURING ADJUVANT FLUOROPYRIMIDINE -

  OXALIPLATIN CHEMOTHERAPY ON THE OUTCOME OF PATIENTS WITH RESECTED COLON CANCER:

  A TOSCA STUDY SUBANALYSIS

Scarica il file  

· TOSCA IDEA: RIFLESSIONI E COMMENTI

Scarica il file  

· NEWSLETTER

Scarica il file  

· FOLFOX OR CAPOX IN STAGE II TO III COLON CANCER: EFFICACY RESULTS OF THE ITALIAN THREE

  OR SIX COLON ADJUVANT TRIAL

​

Scarica il file  

· THE HARD ROAD TO DATA INTERPRETATION: THREE OR SIX MONTHS OF ADJUVANT

  CHEMOTHERAPIE FOR PATIENTS WITH STAGE III COLON CANCER?

Scarica il file  

· DURATION OF ADJUVANT CHEMOTHERAPY FOR STAGE III COLON CANCER

Scarica il file  

· PHASE III TRIAL COMPARING 3-6 MONTHS OF ADJUVANT FOLFOX4/XELOX IN STAGE II-III COLON     CANCER: SAFETY AND COMPLIANCE IN THE TOSCA TRIAL

Scarica il file  

· GENETIC MARKERS FOR TOXICITY OD ADJUVANT OXALIPLATIN AND FLUOROPYRIMIDINES IN THE   PHASE III TOSCA TRIAL IN HIGH-RISK COLON CANCER PATIENTS

Scarica il file  

· DIHYDROPYRIMIDINE DEHYDROGENASE PHARMACOGENETICS FOR PREDICTING  

  FLUOROPYRIMIDINE-RELATED TOXICITY IN THE RANDOMIZED, PHASE III ADJUVANT TOSCA TRIAL

  IN HIGH-RISK COLON CANCER PATIENTS

· ABSTRACT ASCO 2017 - ORAL PRESENTATION

Scarica il file  

Scarica il file  

Scarica il file